Additional file 1 of Cumulative dose of epinephrine and mode of death after non-shockable out-of-hospital cardiac arrest: a registry-based study
Creators: name: Javaudin, François
name: Bougouin, Wulfran
name: Fanet, Lucie
name: Diehl, Jean-Luc
name: Jost, Daniel
name: Beganton, Frankie
name: Empana, Jean-Philippe
name: Jouven, Xavier
name: Adnet, Frédéric
name: Lamhaut, Lionel
name: Lascarrou, Jean-Baptiste
name: Cariou, Alain
name: Dumas, Florence
Publisher: name: figshare
Year: 2023
Subjects: Medicine
Neuroscience
Pharmacology
Biological Sciences not elsewhere classified
Cancer
Science Policy
Mental Health

description: Additional file 1. Table S1. Characteristics of study population according to epinephrine dose administered during CPR CPR, cardiopulmonary resuscitation; PEA, pulseless electrical activity; CA, cardiac arrest; ECMO, extracorporeal membrane oxygenation; TTM, targeted temperature management Table S2. Multinomial regression after multiple data imputation (n = 2,792), reference population: alive at hospital discharge (full model) CPR, cardiopulmonary resuscitation; PEA, pulseless electrical activity; ECMO, extracorporeal membrane oxygenation; TTM, targeted temperature management. Table S3. Multinomial regression without multiple data imputation (n = 2,037), reference population: alive at hospital discharge Adjustment variables: gender, age, location, witnessed OHCA, bystander CPR, no-flow duration, initial electrical rhythm, low-flow duration, medical history: heart disease, cancer, renal disease, high blood pressure; ECMO use, coronary angioplasty intervention, TTM, post resuscitation shock, presumed cardiac cause. Table S4. Sensitivity analysis (+ years) after multiple data imputation (n = 2,792), reference population: alive at hospital discharge Adjustment variables: gender, age, location, witnessed OHCA, bystander CPR, no-flow duration, initial electrical rhythm, low-flow duration, medical history: heart disease, cancer, renal disease, high blood pressure; ECMO use, coronary angioplasty intervention, TTM, post resuscitation shock, presumed cardiac cause, years. Table S5. Sensitivity analysis (+ years) without multiple data imputation (n = 2,037), reference population: alive at hospital discharge. Adjustment variables: gender, age, location, witnessed OHCA, bystander CPR, no-flow duration, initial electrical rhythm, low-flow duration, medical history: heart disease, cancer, renal disease, high blood pressure; ECMO use,coronary angioplasty intervention, TTM, post resuscitation shock, presumed cardiac cause, years. Table S6. Sensitivity analysis, epinephrine as continuous variable, reference population: alive at hospital discharge Adjustment variables: gender, age, location, witnessed OHCA, bystander CPR, no-flow duration, initial electrical rhythm, low-flow duration, medical history: heart disease, cancer, renal disease, high blood pressure; ECMO use, coronary angioplasty intervention, TTM, post resuscitation shock, presumed cardiac cause, years. Table S7. Sensitivity analysis according to low-flow duration (tertiles), reference population: alive at hospital discharge Adjustment variables: gender, age, location, witnessed OHCA, bystander CPR, no-flow duration, initial electrical rhythm, low-flow duration, medical history: heart disease, cancer, renal disease, high blood pressure; ECMO use, coronary angioplasty intervention, TTM, post resuscitation shock, presumed cardiac cause. Figure S1. Linear regression of the low-flow duration (minutes) in relation to epinephrine dose used during CPR (mg). Figure S2. Linear regression of the proportion of deaths from cardiovascular causes (CCD, cardiovascular death) in relation to epinephrine dose used during CPR. Figure S3. Total epinephrine dose used during CPR in the complete population of the study. Figure S4. Percentage proportion of epinephrine use during CPR by outcome. Figure S5. Number of subjects by epinephrine dose used during CPR and outcome.